756 results on '"Landgren O"'
Search Results
2. Second primary malignancies in multiple myeloma: an overview and IMWG consensus
3. Early life dietary pattern and risk of monoclonal gammopathy of undetermined significance: Marianna Thordardottir
4. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis
5. Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study
6. S177: EVALUATING SERUM FREE LIGHT CHAIN RATIO AS A BIOMARKER FOR MULTIPLE MYELOMA
7. P886: AFRICAN AMERICAN PATIENTS WITH SMOLDERING MULTIPLE MYELOMA MAY HAVE A LOWER RISK OF PROGRESSION COMPARED TO WHITE PATIENTS
8. Plasma Cell Neoplasms in US Solid Organ Transplant Recipients
9. MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients
10. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
11. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
12. Pain and anxiety during bone marrow aspiration/biopsy: Comparison of ratings among patients versus health-care professionals
13. Circulating Antibody Free Light Chains and Risk of Posttransplant Lymphoproliferative Disorder
14. Risk of myeloid neoplasms after solid organ transplantation
15. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia
16. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey
17. Update on second primary malignancies in multiple myeloma: a focused review
18. Bildgebung bei „smoldering“ (asymptomatischem) multiplem Myelom: Vergangenheit, Gegenwart und Zukunft
19. Inherited genetic susceptibility to multiple myeloma
20. Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial
21. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance
22. Brain tumors in patients with myotonic dystrophy: a population-based study
23. Serum immunoglobulin free light chains and post-transplant lymphoproliferative disorder among allogeneic hematopoietic stem cell transplant recipients
24. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
25. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
26. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS
27. Cure with heart in mind!
28. Improved long-term survival in multiple myeloma up to the age of 80 years
29. Supplement to: Bortezomib to treat the TEMPI syndrome.
30. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
31. Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management
32. Supplement to: Myeloma and second primary cancers.
33. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis
34. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
35. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
36. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients
37. Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkin's disease
38. Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study
39. Plasma Cell Neoplasms among Solid Organ Transplant Recipients.: Abstract# 527
40. Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma
41. Corrigendum: Second primary malignancies in multiple myeloma: an overview and IMWG consensus
42. Procedure-related pain among adult patients with hematologic malignancies
43. Improved Survival in Younger Patients with Multiple Myeloma: A Population-Based Study from Malmö, Sweden: A109
44. Incidence of Myeloma Over 56 Years (1950-2006): A Population-Based Study from Malmö, Sweden: A091
45. Use of hair colouring products and risk of multiple myeloma among US women
46. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma response assessment and diagnosis system (MY-RADS)
47. PAIN FOLLOWING BONE MARROW ASPIRATION IN ADULTS: 970
48. Risk profile and outcome in Hodgkinʼs lymphoma: is obesity beneficial?
49. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkinʼs lymphoma
50. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.